Clinical trial
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without…
NCT00003440 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003440 |
|---|---|
| Title | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic |
| Official title | A Phase III Study of Paclitaxel Via Weekly 1 Hour Infusion Versus Standard 3 Hour Infusion Every 3 Weeks With Herceptin (Trastuzumab) (NSC #688097) in the Treatment of Patients With/Without HER-2/Neu-Overexpressing Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | paclitaxel, trastuzumab, quality-of-life assessment, laboratory biomarker analysis |
| Enrollment | 580 |
| Start date | Jul 1, 1998 |
| Primary completion | Jul 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: